We develop transformative medicines and technologies by building agile, focused companies called Vants.
Roivant was founded in 2014 with the aim to improve the lives of patients by accelerating the development and commercialization of medicines that matter.
01
Roivant builds nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies
Our Vants have conducted 12 positive Phase 3 trials since 2019, and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults
02
2nd Successful Roivant Commercial Launch
1) In 2026, we launched LISRAYA (brepocitinib) for adults with dermatomyositis. 2) In 2022, we launched VTAMA (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults.
03
Diverse leadership and employee base
We have worked to ensure an open, diverse, and inclusive culture, while building a leadership team, board of directors and broader employee base that reflects these values.
